{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T23:01:17Z","timestamp":1771801277290,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,21]]},"DOI":"10.7759\/cureus.92835","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T11:48:17Z","timestamp":1758455297000},"source":"Crossref","is-referenced-by-count":1,"title":["Wild-Type Transthyretin Amyloid Cardiomyopathy With Bone Marrow Involvement: Clinical Implications of Less Common Sites of Amyloid Deposition"],"prefix":"10.7759","author":[{"given":"Yusuke","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneaki","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kae","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moroe","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michifumi","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore JD","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al.. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024, 390:132-42. 10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana M","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, et al.. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025, 392:33-44. 10.1056\/NEJMoa2409134","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H, et al.. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021, 289:268-92. 10.1111\/joim.13169","journal-title":"J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala V","year":"2024","unstructured":"Sanchorawala V. Systemic light chain amyloidosis. N Engl J Med. 2024, 390:2295-307. 10.1056\/NEJMra2304088","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/pin.13041","article-title":"Distribution of amyloidosis subtypes based on tissue biopsy site - consecutive analysis of 729 patients at a single amyloidosis center in Japan","volume":"71","author":"Abe R","year":"2021","unstructured":"Abe R, Katoh N, Takahashi Y, et al.. Distribution of amyloidosis subtypes based on tissue biopsy site - consecutive analysis of 729 patients at a single amyloidosis center in Japan. Pathol Int. 2021, 71:70-9. 10.1111\/pin.13041","journal-title":"Pathol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin\u00a0cardiac amyloidosis and\u00a0risk stratification using a novel\u00a0staging system","volume":"68","author":"Grogan M","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, et al.. Natural history of wild-type transthyretin\u00a0cardiac amyloidosis and\u00a0risk stratification using a novel\u00a0staging system. J Am Coll Cardiol. 2016, 68:1014-20. 10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore JD","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al.. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018, 39:2799-806. 10.1093\/eurheartj\/ehx589","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002877","article-title":"Subtype-specific interactions and prognosis in cardiac amyloidosis","volume":"5","author":"Sperry BW","year":"2016","unstructured":"Sperry BW, Vranian MN, Hachamovitch R, Joshi H, Ikram A, Phelan D, Hanna M. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc. 2016, 5:e002877. 10.1161\/JAHA.115.002877","journal-title":"J Am Heart Assoc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2031963","article-title":"Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution","volume":"29","author":"Chiu A","year":"2022","unstructured":"Chiu A, Dasari S, Kurtin PJ, et al.. Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. Amyloid. 2022, 29:156-64. 10.1080\/13506129.2022.2031963","journal-title":"Amyloid"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1309\/PFUG-HBX0-TY20-E08U","article-title":"Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases","volume":"120","author":"Swan N","year":"2003","unstructured":"Swan N, Skinner M, O'Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003, 120:610-6. 10.1309\/PFUG-HBX0-TY20-E08U","journal-title":"Am J Clin Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1314959","article-title":"Amyloid in bone marrow smears in systemic light-chain amyloidosis","volume":"24","author":"Kimmich C","year":"2017","unstructured":"Kimmich C, Sch\u00f6nland S, Kr\u00e4ker S, et al.. Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid. 2017, 24:52-9. 10.1080\/13506129.2017.1314959","journal-title":"Amyloid"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine NM","year":"2014","unstructured":"Fine NM, Arruda-Olson AM, Dispenzieri A, et al.. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014, 113:1723-7. 10.1016\/j.amjcard.2014.02.030","journal-title":"Am J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415707-wild-type-transthyretin-amyloid-cardiomyopathy-with-bone-marrow-involvement-clinical-implications-of-less-common-sites-of-amyloid-deposition","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T11:48:18Z","timestamp":1758455298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415707-wild-type-transthyretin-amyloid-cardiomyopathy-with-bone-marrow-involvement-clinical-implications-of-less-common-sites-of-amyloid-deposition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,21]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.92835","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,21]]}}}